Comparative Cardiovascular Outcomes Across PCSK9-Targeted Therapies: A Real-World Matched Cohort Analysis of Inclisiran, Alirocumab, and Evolocumab (AHA 2026) - Sep 5, 2026 - Abstract #Su4079; Pres time: Nov 8, 2026; 03:15 PM - 04:15 PM; Location: Basic Science Zone‚ Science and Technology Hall‚ South Hall‚ Level 3; In-Person; Board no. 4079; No abstract available
Clinical • Real-world • Real-world evidence • Cardiovascular
|
|
Yesh Dhruva; Alex Iorfida; Chien-Jung Lin; Nicholas Mootz; Rohit Ponnada
|